Imatinib Completed Phase 2 Trials for Life Threatening Diseases Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00154388Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases